MannKind Reports Q1 2026 Earnings with Revenue Growth and Key Product Updates
MannKind (MNKD) reported Q1 2026 earnings with revenue of $90 million, a 15% increase driven by contributions from FURO6. The company highlighted strong growth in FURO6 net sales and new product milestones, including a $5 million payment from United Therapeutics. However, GAAP net loss widened to $16.6 million compared to a net income of $13.2 million in the same period last year.
Topics: financial_results milestones product_performance revenue_growth